Introduction
Matrix metalloproteinase (MMP) 9 is upregulated following various types of insults to the brain, and has been suggested as a marker of neurodegeneration [1] [2] [3] [4] [5] . Recent studies, however, have also implicated MMP9 in neural remodeling [4, [6] [7] [8] [9] [10] [11] [12] , making it unclear whether increased expression of MMP9 contributes to damage or recovery from damage in the central nervous system. The psychomotor stimulant methamphetamine upregulates MMP9, and recent studies suggest that this contributes to neural remodeling [13] [14] [15] . The involvement of MMP9 in methamphetamine-induced neurotoxicity, however, remains unclear and was thus evaluated in this study.
Methods

Mice
Male, Swiss Webster (Harlan, Indianapolis, Indiana, USA), FVB, and MMP9 À/À (Jackson Laboratory, Bar Harbor, Maine, USA) mice were used. Animal procedures were conducted as approved by the Institutional Animal Care and Use Committee at each participating university.
Drugs
Methamphetamine hydrochloride (Research Biochemicals International, Natick, Massachusetts, USA) was administered to the mice as either a large bolus (40 mg/kg) or using a repeated dosing schedule to achieve the same cumulative dose (10 mg/kg, 4 Â 2 h intervals) [16] . For the time course studies, bolus injections were given to facilitate determining the progression of the gene expression changes. As more deaths, however, resulted after bolus injections of the high methamphetamine dose, as compared with repeated administrations to the same cumulative dose, for the studies involving MMP9 knockout mice, the repeated dosing schedule was used.
Time course
Swiss Webster mice were injected with methamphetamine (1, 10, or 40 mg/kg, intraperitoneally) and their brains collected at designated time points. For earlier time points (5 min to 24 h), which precede the development of neurotoxicity, MMP9 gene expression was determined in whole brain. For the later time points during which neurotoxicity develops (days 1, 2, 3, 7), MMP9 gene expression was measured in half brain and also striatum, a brain region profoundly affected by methamphetamine neurotoxicity [17] [18] [19] .
Real time PCR MMP9 gene expression was quantified using real time PCR. Total RNA was extracted from each sample using Trizol reagents, followed by first strand cDNA synthesis using 'Superscript' II RNase H Reverse Transcriptase (Gibco BRL, Life Technologies, Rockville, Maryland, USA) and random decamers (Ambion, Austin, Texas, USA). Primer Express software (Applied Biosystems, Foster City, California, USA) was used to design upper (CACCTTCACCCGCGTGTAC) and lower (TGCTCCGCGACACCAAA) primers, and a stock solution prepared by diluting the oligos to 100 pmol/ml in sterile water. Each PCR was composed of 2 ml cDNA template, 12.5 ml master mix, 0.125 ml of each primer (upper and lower), and 10.25 ml sterile water. Thermal cycling, using an ABI PRISM 7000 Sequence Detection System (Applied Biosystems), was initiated at 501C for 2 min, followed by a first denaturing step at 951C for 10 min, and then 40 cycles at 951C for 15 s, and at 601C for 1 min. Threshold cycle (Ct) was determined using SDS software (Applied Biosystems) and relative gene expression levels evaluated by the DDCt method. 28s Ribosomal RNA was used as a reference.
Matrix metalloproteinase 9 knockout mice MMP9 À/À and wild-type FVB control mice were injected with methamphetamine (0-10 mg/kg, 4 Â 2 h intervals), and body temperature measured 1 h after each injection. One week after the treatments, the brains were collected and striatal dopamine levels measured using a Dopamine Research Enzyme Immunoassay kit and protocols supplied by the manufacturer (Rocky Mountain Diagnostics, Colorado Springs, Colorado, USA). A separate group of mice were injected with a stimulant dose of methamphetamine (1 mg/kg, intraperitoneally) once a day for 9 consecutive days and locomotor activity measured for 90 min using an automated activity monitoring system (San Diego Instruments, San Diego, California, USA) to quantify the development of behavioral sensitization.
Results
Time course of matrix metalloproteinase 9 gene expression Analysis of variance revealed a significant effect of time [F(9,105)¼3.87, Po0.0005]. As shown in Fig. 1 , treatment with methamphetamine upregulated MMP9 gene expression within 5 min. At 24 h, MMP9 gene expression returned to control levels in the stimulant (1 mg/kg)-treated mice, but remained elevated in animals exposed to higher (10 and 40 mg/kg) doses of methamphetamine (post-hoc tests 0 vs. 24 h, Po0.01). Neurotoxicity was evident at 1-7 days after methamphetamine exposure as depletions in striatal dopamine levels (Fig. 2) . Two-way analysis of variance confirmed a significant effect of methamphetamine dose [F(2,47)¼10.25, Po0.0005]. In mice treated with the neurotoxic 40 mg/kg dose of methamphetamine, however, there was a lack of correlation between striatal dopamine levels, a well-established marker of methamphetamine neurotoxicity, and MMP9 gene expression in the half brain (r 2 ¼0.18, NS) or striatum (r 2 ¼0.53, NS).
Effects of methamphetamine in matrix metalloproteinase 9 À/À mice In MMP9 knockout mice, neurotoxic dosing with methamphetamine produced increases in body temperature [F(4,20) ¼5.88-14.97, Po0.005-0.0001] and depletions in striatal dopamine levels [F(4,19)¼56.21, Po0.0001] that were comparable with wild-type mice (Fig. 3) . Although the absence of MMP9 did not affect methamphetamine neurotoxicity, the knockout mice exhibited the expected decrease in behavioral sensitization after repeated administration of stimulant doses of methamphetamine ( Fig. 4 ).
Discussion
Treatment with methamphetamine resulted in a rapid upregulation of MMP9 gene expression, which was measurable Background DA level (% control) Fig. 3 E¡ect of neurotoxic dosing with methamphetamine in matrix metalloproteinase 9 (MMP9) À/À mice. MMP9 knockout mice exhibited methamphetamine-induced neurotoxicity, as measured as depletions in striatal dopamine levels, which were comparable with background mice. DA, dopamine; i.p., intraperitoneally.
within minutes. By 24 h, MMP9 gene expression returned to control levels in stimulant-treated mice, but remained elevated in animals exposed to higher doses of methamphetamine. To determine if the elevated levels of MMP9 gene expression were associated with the development of neurotoxicity, striatal dopamine levels and MMP9 gene expression were monitored 1-7 days after methamphetamine exposure. During this time frame in which methamphetamine neurotoxicity develops [20, 21] , there was the expected depletion in striatal dopamine levels in mice exposed to toxic doses of methamphetamine. This well-established marker of methamphetamine neurotoxicity, however, was not accompanied by concomitant changes in MMP9 gene expression, suggesting that MMP9 gene expression does not serve as a marker for neurodegeneration in methamphetamine-induced neurotoxicity, as it seems to follow some types of strokes [5, 11, 22, 23] . To determine if MMP9 protein expression has consequences for methamphetamine neurotoxicity, MMP9 knockout mice were treated with methamphetamine. Mice lacking MMP9 still developed hyperthermia and neurotoxicity to methamphetamine. Similar to an earlier study [13] [14] [15] , MMP9 knockout mice, however, exhibited a reduced response to the locomotor sensitizing effects of methamphetamine, an effect that is thought to involve remodeling of the nervous system.
Conclusion
Together, the data suggest that changes in MMP9 expression do not affect methamphetamine-induced neurotoxicity, and may instead contribute to remodeling of the nervous system. 
